Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 May 24;30(6):5227-5239.
doi: 10.3390/curroncol30060397.

A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series

Ioannis A Voutsadakis  1   2
Affiliations
Meta-Analysis

A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series

Ioannis A Voutsadakis. Curr Oncol. .

Abstract

Background: Colorectal cancer is the most prevalent gastrointestinal neoplasm. When metastatic, the disease has limited systemic treatment options. Novel targeted therapies have expanded these options for subsets with specific molecular alterations, such as microsatellite instability (MSI)-high cancers, but additional treatments and combinations are in urgent need to improve outcomes and improve survival of this incurable disease. The fluoropyrimidine-derivative trifluridine, in combination with tipiracil, has been introduced as a third-line treatment, and more recently, it was studied in combination with bevacizumab. This meta-analysis reports on studies with this combination in clinical practice outside clinical trials.

Methods: A literature search in the Medline/PubMed and Embase databases was executed for finding series of trifluridine/tipiracil with bevacizumab in metastatic colorectal cancer. Criteria for inclusion in the meta-analysis were English or French language of the report, inclusion of twenty or more patients with metastatic colorectal cancer treated with trifluridine/tipiracil in combination with bevacizumab outside of a trial and containing information regarding response rates, progression-free survival (PFS), and overall survival (OS). Information on the demographics of the patients and on adverse effects of treatment was also collected.

Results: Eight series with a total of 437 patients were eligible for the meta-analysis. The performed meta-analysis discovered a summary response rate (RR) of 2.71% (95% confidence interval (CI): 1.11-4.32%) and a disease control rate (DCR) of 59.63% (95% CI: 52.06-67.21%). Summary PFS was 4.56 months (95% CI: 3.57-5.55 months), and summary OS was 11.17 months (95% CI: 10.15-12.19 months). Common adverse effects identified mirrored the adverse-effect profile of the two components of the combination.

Conclusion: The current systematic review and meta-analysis reports the efficacy of trifluridine/tipiracil with bevacizumab in advanced lines of therapy for metastatic colorectal cancer in the setting of clinical practice outside clinical trials. Discovery of predictive biomarkers of response to trifluridine/tipiracil with bevacizumab will promote the tailoring of this treatment to individual patients to maximize clinical benefit.

Keywords: TAS-102; anti-angiogenic; colorectal cancer; later line; metastatic.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the research articles screened and selected for the meta-analysis.
Figure 2
Figure 2
Meta-analysis of response rate (RR) [18,19,20,21,22,23,24,25].
Figure 3
Figure 3
Meta-analysis of disease control rate (DCR) [18,19,20,21,22,23,25].
Figure 4
Figure 4
Meta-analysis of progression-free survival (PFS) [18,19,20,21,22,23,24].
Figure 5
Figure 5
Meta-analysis of overall survival (OS) [18,19,20,21,22,23,24,25].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Sauer A.G., Fedewa S.A., Butterly L.F., Anderson J.C., Cercek A., Smith R.A., Jemal A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020;70:145–164. doi: 10.3322/caac.21601. - DOI - PubMed
    1. Riedesser J.E., Ebert M.P., Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther. Adv. Med. Oncol. 2022;14:17588359211072703. doi: 10.1177/17588359211072703. - DOI - PMC - PubMed
    1. Rankin A., Klempner S.J., Erlich R., Sun J.X., Grothey A., Fakih M., George T.J., Jr., Lee J., Ross J.S., Stephens P.J., et al. Broad Detection of Alterations Predicted to Confer Lack of Benefit from EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist. 2016;21:1306–1314. doi: 10.1634/theoncologist.2016-0148. - DOI - PMC - PubMed
    1. Tabernero J., Grothey A., Van Cutsem E., Yaeger R., Wasan H., Yoshino T., Desai J., Ciardiello F., Loupakis F., Hong Y.S., et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J. Clin. Oncol. 2021;39:273–284. doi: 10.1200/JCO.20.02088. - DOI - PMC - PubMed

MeSH terms